透析膜の生体適合性

出版社： 東京医学社
著者：
発行日： 2010-03-25
分野： 基礎・関連科学  >  医用工学/材料
ISBN： 9784885631948
電子書籍版： 2010-03-25 （第1版）
書籍・雑誌
≪全国送料無料でお届け≫
品切れ

3,960 円(税込)

電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

3,960 円(税込)

購入する

商品紹介

透析医療の研究の足跡を解説するとともに、現在の生体適合性、透析膜−血液相互細孔径反応、高齢者透析などの研究の先端の現況を紹介。今後の透析医療や研究の方向性を示す。

目次

  • 透析膜の生体適合性

    ―目次―

    1．生体適合性とは
    2．生体適合性の指標
    3．透析膜の表面特性と蛋白質吸着
    4．EVAL膜の溶質除去特性
    5．透析膜生体適合性の臨床的側面
    　　―MIA症候群予防におけるEVAL膜の有用性
    6．血液透析膜による血液細胞の活性化と細胞接着
    　　―P-セレクチンを介する血小板-白血球複合体の形成
    7．Heterotypic Cell Interactions in Hemodialysis Patients
    　　（血液透析患者における血液細胞間の相互作用）
    8．Biocompatibility profile of Ethylen-vinyl-alcohol(EVAL),
    a synthetic dialytic membrane with reduced coagulation
    and inflammatory activity
    　　（凝固系活性化および催炎症作用が少ない合成透析膜
    　　　「エチレンビニルアルコール（EVAL膜）」の
    　　　生体適合性の特長）
    9．蛋白リーク膜の溶質除去と臨床効果
    10．微小循環に対する透析膜の影響
    11．EVAL膜による透析患者の栄養状態の改善
    12．血圧低下の防止―EK(EVAL)膜による透析低血圧の予防
    13．高齢者社会の維持透析―現状とあり方―

    トピックス　生体適合性の考え方の変遷と病態評価

    コラム1　透析膜の高次機能
    コラム2　Hight preformance membraneの思い出

    座談会　Biocompatible membraneの将来
    　　　　　―透析萌芽期の若手からの提言

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

1 生体適合性とは

P.7 掲載の参考文献
1) Hakim RM : Clinical implications of hemodialysis membrane biocompatibility. Kidney Int 44 : 484-494, 1993
PubMed
2) Ing TS, Daugirdas JT, Popli S, et al : First-use syndrome with cuprammonium cellulose dialyzer. Int J Artif Organs 6 : 235-239, 1983
PubMed
3) Craddock PR, Hammerschmidt D, White JG, et al : Complement (C5a) -induced granulocyte aggregation in vitro. A possible mechanism of complement-mediated leukostasis and leukopenia. J Clin Invest 60 : 260-264, 1977
PubMed
4) Arnaout MA, Hakim RM, Todd RF, et al : Increased expression of an adhesion-promoting surface glycoprotein in the granulocytopenia of hemodialysis. N Engl J Med 312 : 457-462, 1985
PubMed
5) Cheung AK, Chenoweth DE, Otsuka D, et al : Compartmental distribution of complement activation products in artificial kidneys. Kidney Int 30 : 74-80, 1986
PubMed
6) Combe C, Pourtein M, de Precigout V, et al : Granulocyte activation and adhesion molecules during hemodialysis with cuprophane and a high-flux biocompatible membrane. Am J Kidney Dis 24 : 437-442, 1994
 
7) Descamps-Latscha B, Goldfarb B, Nguyen AT, et al : Establishing the relationship between complement activation and stimulation of phagocyte oxidative metabolism in hemodialyzed patients : a randomized prospective study. Nephron 59 : 279-285, 1991
PubMed
8) Tielemans C, Madhoun P, Lenaers M, et al : Anaphylactoid reactions during hemodialysis on AN69 membranes in patients receiving ACE inhibitors. Kidney Int 38 : 982-984, 1990
PubMed
9) Verresen L, Fink E, Lemke HD, et al : Bradykinin is a mediator of anaphylactoid reactions during hemodialysis with AN69 membranes. Kidney Int 45 : 1497-1503, 1994
PubMed
10) Olbricht CJ, Schaumann D, Fischer D : Anapylactoid reaction, LDL apheresis with dextran sulfate, and ACE inhibitors. Lancet 340 : 908-909, 1992
 
11) Henderson LW, Koch KM, Dinarello CA, et al : Hemodialysis hypotension : the interleukin-1 hypothesis. Blood Purif 1 : 3-8, 1983
 
12) Lonnemann G, Behme TC, Lenzner B, et al : Permeability of dialyzer membranes to TNF alphainducing substances derived from water bacteria. Kidney Int 42 : 61-68, 1992
 
13) Evans RC, Holmes CJ: In vitro study of the transfer of cytokine-inducing substances across selected high-flux hemodialysis membranes. Blood Purif 9 : 92-101, 1991
PubMed
14) Schindler R, Beck W, Deppisch R, et al : Short bacterial DNA fragments : detection in dialysate and induction of cytokines. J Am Soc Nephrol 15 : 3207-3214, 2004
PubMed
15) Stenvinkel P : Inflammatory and atherosclerotic interactions in the depleted uremic patient. Blood Purif 19 : 53-61, 2001
 
16) Ward R, Klein E, Harding G, et al : Response of complement and neutrophils to hydrophilized synthetic membranes. Trans ASAIO 34 : 334-337, 1988
PubMed
17) 藤森明, 内藤秀宗, 鈴木正司, 他 : ポリスルフォン膜におけるアナフィラキシー様反応に関する一考察. 腎と透析 47 別冊ハイパフォーマンスメンブレン '99 : 163-166, 1999
 
18) Pascual M, Schifferli JA : Adsorption of complement factor D by polyacrylonitrile dialysis membranes. Kidney Int 43 : 903-911, 1993
PubMed
19) National kidney foundation : Clinical practice guideline for hemodialysis adequacy, update 2006. Am J Kidney Dis 48 (suppl 1) : S2-S90, 2006
 
20) European Best Practice Guidelines Expert Group on Haemodialysis, European Renal Association (Part 1), Section III Biocompatibility. Nephrol Dial Transplant 17 (suppl 7) : 32-44, 2002
 

2 生体適合性の指標

P.14 掲載の参考文献
1) Craddock P, Fehr J, Brighamk K, et al : Pulmonary capillary leukostasis-complement (C') mediated complication of hemodialysis. Clin Res 23 : A402-A402, 1975
 
2) 武本佳昭, 松田武久, 小関英一, 他 : 細胞内Caイオン動態を指標とする新しい人工透析膜の生体適合性評価法の開発. 人工臓器 18 : 1185-1190, 1989
 
3) Itoh S, Suzuki C, Tsuji T : Platelet activation through interaction with hemodialysis membranes induces neutrophils to produce reactive oxygen species. J Biomed Mater Res 77A : 294-303, 2006
 
4) 内藤秀宗, 宮崎哲夫, 高木俊昭, 他 : 各種透析膜の血液凝固系に与える影響. 人工臓器 16 : 763-766, 1987
 
5) von Sengbush G, Baurmeister U, Vienken J : Adaptability of cellulosic membranes to different biocompatibility parameters. Contri Nephrol 59 : 126-133, 1987
 
6) Horl WH, Riegel W, Steinhaur HB, et al : Plasma levels of main granulocyte components during hemodialysis. Contri Nephrol 59 : 35-43, 1987
 
7) Sirolli V, Ballone E, Diliberato L, et al : Leukocyte adhesion molecules and leukocyte-platelet interactions during hemodialysis : effects of different synthetic membranes. International J Artificial Organs 22 : 536-542, 1999
 
8) Memoli B,Grandaliano G, Soccio M, et al : In vivo modulation of soluble antagonistic IL-6 receptor synthesis and release in ESRD. J Am Soc of Nephrol 16 : 1099-1107, 2005
PubMed
9) 中辻史好, 米田龍生, 影林頼明 : 透析膜生体適合性評価におけるHPLCによる血清ネオプテリン測定の有用性-ビタミンE固相化改質セルロース膜における基礎的・臨床的評価. 奈良医誌 50 : 174-182, 1999
 

3 透析膜の表面特性と蛋白質吸着

P.25 掲載の参考文献
1) 岩田博夫 : 高分子先端材料One Point 3バイオマテリアル, 高分子学会編, 共立出版, 東京, 2005
 
2) Sigal GB, Marksich M, Whitesides GM : Effect of surface wettability on the adsorption of proteins and detergents. J Am Chem Soc 120 : 3464-3473,1998
 
3) Prime KL, Whitesides GM : Adsorption of proteins onto surfaces containing end-attached oligo (ethylene oxide) : a model system using self-assembled monolayers. J Am Chem Soc 115 : 10714-10721, 1993
 
4) Lestelius M, Liedberg B, Tengvall P : In vitro plasma protein adsorption on ω-functionalized alkanethiolate self-assembled monolayers. Langmuir 13 : 5900-5908, 1997
 
5) Zhang Z, Zhang M, Chen S, et al : Blood compatibility of surfaces with superlow protein adsorption. Biomaterials 29 : 4285-4291, 2008
 
6) Hayama M, Kohori F, Sakai K : AFM observation of small surface pores of hollow-fiber dialysis membrane using highly sharpened probe. J Membrane Sci 197 : 243-249, 2002
 
7) Mitsui K, Nakajima K, Arakawa H, et al : Dynamic measurement of single protein's mechanical properties. Biochem Biophys Res Commun 272 : 55-63, 2000
PubMed
8) 猪飼篤, Afrin R, Wang T, 他 : たんぱく質分子の力学物性と吸着力測定. 応用物理 72 : 1300-1303, 2003
 
9) Greca GL, Ronco C : Cellulose Triacetate-Evaluation of a Dialysis Membrane-, Witchig Editore, Italy, 1994
 
10) Fukuda M, Miyazaki M, Hiyoshi T, et al : Newly developed biocompatible membrane and effects on its smoother surface on antithrombogenicity. J Appl Polym Sci 72 : 1249-1256, 1999
 
11) Tsunoda N, Kokubo K, Sakai K, et al : Surface roughness of cellulose hollow fiber dialysis membranes and platelet adhesion. ASAIO J 45 : 418-423, 1999
PubMed
12) Hayama M, Yamamoto K, Kohori F, et al : Nanoscopic behavior of polyvinylpyrrolidone particles on polysulfone/polyvinylpyrrolidone film. Biomaterials 25 : 1019-1028, 2004
PubMed
13) Matsuda M, Yamamoto K, Yakushiji T, et al : Nanotechnological evaluation of protein adsorption on dialysis membrane surface hydrophilized with polyvinylpyrrolidone. J Membrane Sci 310 : 219-228, 2008
 
14) Namekawa K, Fukuda M, Matsuda M, et al : Nanotechnological characterization of human serum albumin adsorption on wet synthetic polymer dialysis membrane surfaces. ASAIO J 55 : 236-242, 2009
PubMed
15) Hayama M, Yamamoto K, Kohori F, et al : How polysulfone dialysis membranes containing polyvinylpyrrolidone achieve excellent biocompatibility? J Membrane Sci 234 : 41-49, 2004
 
16) Matsuda M, Sato M, Sakata H, et al : Effects of fluid flow on elution of hydrophilic modifier from dialysis membrane surfaces. J Artif Organs 11 : 148-155, 2008
PubMed
17) 滑川亘希, 松田雅人, 八木優, 他 : EVAL透析膜とPVP配合合成高分子膜のHSA吸着力の比較. 腎と透析 67 別冊ハイパフォーマンス・メンブレン '09 : 127-131, 2009
 

4 EVAL膜の溶質除去特性

P.34 掲載の参考文献
1) 垣内智樹 : 非対称構造EVAL透析膜の開発. 腎と透析 57 別冊 ハイパフォーマンスメンブレン '04 : 73-76, 2004
 
2) 及川一彦, 中鉢俊成, 三谷盛, 他 : EVAL-CH膜 (EV-15CH) の性能評価. 腎と透析 38 別冊ハイパフォーマンスメンブレン '95 : 166-169, 1995
 
3) 及川一彦, 清水正明, 三谷盛, 他 : EVAL膜 (KF-C) の溶質および体液の細胞内外移動に対する影響. 腎と透析 43 別冊ハイパフォーマンスメンブレン '97 : 83-85, 1997
 
4) 佐藤元美, 依馬弘忠, 森田弘之, 他 : 透析膜の微小循環系への影響とその解析. 腎と透析 55 別冊ハイパフォーマンスメンブレン '03 : 183-186, 2003
 
5) 村上成重, 佐藤弘子, 安藤昭子, 他 : 各種透析膜における末梢循環動態の検討. 腎と透析 55 別冊ハイパフォーマンスメンブレン '03 : 187-191, 2003
 
6) Sirolli V, Ballone E, Di Stante S, et al : Cell activation and cellular-cellular interactions during hemodialysis.Effect of dialyzer membrane. Int J Artif Organs 25 : 529-537, 2002
PubMed
7) Bonomini M, Amoroso L, Di Sante S, et al : 透析膜の生体適合性評価としての細胞-細胞相互作用の研究. 腎と透析 55 別冊ハイパフォーマンスメンブレン '03 : 135-139, 2003
 
8) 森行範, 瀬戸邦雄, 山村桃, 他 : エバブレンEK の溶質除去特性IV型・V型との比較検討. 腎と透析 65 別冊HDF療法 '08 : 244-247, 2008
 
9) 垣内智樹, 関口浩二, 赤松成美, 他 : 新規EVAL透析膜 "エバブレン EK" の除去特性. 腎と透析 63 別冊ハイパフォーマンスメンブレン '07 : 223-226, 2007
 
10) 道脇宏行, 英理香, 細谷陽子, 他 : エバブレンEKの除去特性HDF使用時における検討. 腎と透析 65 別冊ハイパフォーマンスメンブレン '08 : 129-132, 2008
 
11) 藤堂敦, 吉岡正訓, 上野綾子, 他 : EVAL膜ダイアライザEK19性能評価. 腎と透析 63 別冊 ハイパフォーマンスメンブレン '07 : 218-222, 2007
 

5 透析膜生体適合性の臨床的側面 - MIA症候群予防におけるEVAL膜の有用性

P.44 掲載の参考文献
1) 椿原美治編 : 血液透析条件の現況. 図説わが国の慢性透析療法の現況 (2008年12月31日現在), pp28-31, 日本透析医学会統計調査委員会, 2009
 
2) 申曽洙, 西岡正登, 新光聡子, 他 : PS膜透析器との関連が危惧される病態について. 腎と透析 63 別冊ハイパフォーマンスメンブレン '07 : 275-279, 2007
 
3) 政金生人 : 透析方法から考える無愁訴透析. Clinical Engineering 19 (12) : 1219-1224, 2008
 
4) Henderson LW, Koch KM, Shaldon S : Hemodialysis hypotension : The Interleukin hypothesis. Blood Purif 1 : 3-8, 1983
 
5) Colton CK, Ward RA, Shaldon S : Scientific basis for assessment of biocompatibility in extracorporeal blood treatment. Nephrol Dial Transplant 9 (Suppl.2) : 11-17, 1994
 
6) Stenvinkel P, Heimuburger O, Paultre F, et al : Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int 55 : 1899-1911, 1999
 
7) Ivanovich P, Chenoweth DE, et al : Symptoms and activation of granulocytes and complement with two dialysis membranes. Kidney Int 24 : 758-763, 1983
PubMed
8) Gejyo F, Homma N, Suzuki Y, et al : β2-microglobulin-related amyloidosis in patients receiving chronic hemodialysis. Contrib Nephrol 68 : 263-269, 1988
 
9) Floage J, Schaffer J, Koch KM, et al : Dialysis related amyloidosis : A disease of chronic retention and inflammation? Kidney Int 42 (suppl) : 78-85, 1992
 
10) Baz M, Durand C, Ragon A, et al : Using ultrapure water in hemodialysis delays carpal tunnel syndrome. Int J Artif Organs 14 : 681-685, 1991
PubMed
11) Koda Y, Nishi S, Miyazaki S, et al : Switch from conventional to high-flux membrane reduces the risk of carpal tunnel syndrome and mortality of hemodialysis patients. Kidney Int 52 : 1096-1101, 1997
PubMed
12) Wang AY, Woo J, Lam CW, et al : Association of serum fetuin-A malnutrition, inflammation, atherosclerosis and valvular calcification syndrome and outcome in peritoneal dialysis patients. Nephrol Dial Transplant 20 : 1676-1685, 2005
PubMed
13) Kalantar-Zadeh K, Mehrotra R, Fouque D, et al : Metabolic acidosis and malnutrition-inflammation complex syndrome in chronic renal failure. Semin Dial 17 : 455-465, 2004
PubMed
14) 椿原美治編 : (3) 大腿頸部骨折の新規発症に関連する因子に関する解析. 図説わが国の慢性透析療法の現況 (2008年12月31日現在), pp90-104, 日本透析医学会統計調査委員会, 2009
 
15) 秋葉隆編 : X. 血液透析患者の1年生命予後に関する因子O. Kt/V for urea. わが国の慢性透析療法の現況 (2001年12月31日現在), p559, 日本透析医学会統計調査委員会, 2002
 
16) Goodkin DA, Bragg-Gresham Jl, Koenig KG, et al : Association of comorbid conditions and mortality in hemodialysis patients in Europe, Japan, and the United States : The dialysis outcomes and practice patterns study (DOPPS). J Am Soc Nephrol 14 : 3270-3277, 2003
PubMed
17) Okuno S, Ishimura E, Kohno K, et al : Serum beta2-microglobulin level is a significant predictor of mortality in maintenance haemodialysis patients. Nephrol Dial Transplant 24 : 571-577, 2009
PubMed
18) Eknoyan G, Beck GJ, Cheung AK, et al : Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med 347 : 2010-2019, 2002
PubMed
19) Shinzato T, Nakai S, Miwa M, et al : New method to calculate creatinine generation rate using preand postdialysis creatinine concentrations. Artif Organs 21 : 864-872, 1997
 
20) Pisoni R, Wirkstoem B, Akizawa T, et al : Pruiritus in haemodialysis patients : international results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 21 : 3495-3505, 2006
 
21) Lopes AA, Albert JM, Young EW, et al : Screening for depression in hemodialysis patients : Associations with diagnosis, treatment, and outcomes in the DOPPS. Kidney Int 66 : 2047-2053, 2004
PubMed
22) 政金生人 : 愛Pod (patient oriented dialysis) 計画. Clinical Engineering 17 : 157-163, 2006
 
23) 牟田俊幸, 藤本貴之, 原田康雄, 他 : 膜素材の違いにより透析中のアミノ酸漏出に差があるだろうか. 腎と透析 59 別冊ハイパフォーマンスメンブレン '05 : 241-244, 2005
 
24) Sato M, Morita H, Ema H, et al : Effect of different dialyzer membranes on cutaneous microcirculation during hemodialysis. Clin Nephrol 66 : 426-432, 2006
PubMed
25) Sirolli V, Ballone E, Amoroso L, et al : Leukocyte adhesion molecules and leukocyte-platelet interactions during hemodialysis : effects of different synthetic membranes. Int J Artif Organs 22 : 536-542, 1999
PubMed
26) 椿原美治 : 1983年以降導入患者生存率 (年齢別). わが国の慢性透析療法の現況CD-ROM (2007年12月31日現在), 日本透析医学会統計調査委員会, 2008
 
27) 政金生人 : 高齢者にはPSでなくPMMAの方がよい. 腎と透析 63 別冊ハイパフォーマンスメンブレン '07 : 202-204, 2007
 
28) 政金生人 : 栄養学的な見地から見直されてきた前希釈HDFの有効性. Clinical Engineering 18 : 128-133, 2006
 
29) Spalding EM, Chandna SM, Davenport A, et al : Kt/v underestimates the hemodialysis dose in women and small men. Kidney Int 74 : 348-355, 2008
 
30) 椿原美治 : on-pool modelによるKt/V年齢別. わが国の慢性透析療法の現況CD-ROM (2007年12月31日現在), 日本透析医学会統計調査委員会, 2008
 

6 血液透析膜による血液細胞の活性化と細胞接着 - P - セレクチンを介する血小板 - 白血球複合体の形成

P.56 掲載の参考文献
1) Bonomini M, Stuard S, Carreno MP, et al : Neutrophil reactive oxygen species production during hemodialysis : role of activated platelet adhesion to neutrophils through P-selectin. Nephron 75 : 402-411, 1997
PubMed
2) Sirolli V, Ballone E, Di Stante S, et al : Cell activation and cellular-cellular interactions during hemodialysis : effect of dialyzer membrane. Int J Artif Organs 25 : 529-537, 2002
PubMed
3) Nagata K, Tsuji T, Todoroki N, et al : Activated platelets induce superoxide anion release by monocytes and neutrophils through P-selectin (CD62). J Immunol 151 : 3267-3273, 1993
PubMed
4) Nagata K, Tsuji T, Hanai N, et al : Role of O-linked carbohydrate chains on leukocyte cell membranes in platelet-induced leukocyte activation. J Biol Chem 269 : 23290-23295, 1994
 
5) Ruf A, Patscheke H : Platelet-induced neutrophil activation : platelet-expressed fibrinogen induces the oxidative burst in neutrophils by an interaction with CD11C/CD18. Br J Haematol 90 : 791-796, 1995
PubMed
6) Alvarez V, Pulido R, Campanero MR, et al : Differentially regulated cell surface expression of leukocyte adhesion receptors on neutrophils. Kidney Int 40 : 899-905, 1991
PubMed
7) Spangenberg P, Redlich H, Bergmann I, et al : The platelet glycoprotein IIb/IIIa complex is involved in the adhesion of activated platelets to leukocytes. Thromb Haemost 70 : 514-521, 1993
PubMed
8) Johnston GI, Cook RG, McEver RP : Cloning of GMP-140, a granule membrane protein of platelets and endothelium : sequence similarity to proteins involved in cell adhesion and inflammation. Cell 56 : 1033-1044, 1989
PubMed
9) McEver RP : Selectins. Curr Opin Immunol 6 : 75-84, 1994
PubMed
10) Sako D, Chang XJ, Barone KM, et al : Expression cloning of a functional glycoprotein ligand for Pselectin. Cell 75 : 1179-1186, 1993
 
11) Moore KL, Eaton SF, Lyons DE, et al : The P-selectin glycoprotein ligand from human neutrophils displays sialylated, fucosylated, O-linked poly-N-acetyllactosamine. J Biol Chem 269 : 23318-23327, 1994
 
12) Celi A, Pellegrini G, Lorenzet R, et al : P-selectin induces the expression of tissue factor on monocytes. Proc Natl Acad Sci U S A 91 : 8767-8771, 1994
PubMed
13) Koike J, Nagata K, Kudo S, et al : Density-dependent induction of TNF-α release from human monocytes by immobilized P-selectin. FEBS Lett 477 : 84-88, 2000
 
14) Itoh S, Susuki C, Tsuji T : Platelet activation through interaction with hemodialysis membranes induces neutrophils to produce reactive oxygen species. J Biomed Mater Res A 77 : 294-303, 2006
PubMed
15) Nagata K, Tsuji T, Matsushima K, et al : Redistribution of selectin counter-ligands induced by cytokines. Int Immunol 12 : 487-492, 2000
PubMed
16) Itoh S, Susuki, C, Takeshita K, et al : Redistribution of P-selectin glycoprotein ligand-1 (PSGL-1) in chemokine-treated neutrophils : a role of lipid microdomains. J Leukoc Biol 81 : 1414-1421, 2007
PubMed
17) Itoh S, Takeshita K, Susuki C, et al : Redistribution of P-selectin ligands on neutrophil cell membranes and the formation of platelet-neutrophil complex induced by hemodialysis membranes. Biomaterials 29 : 3084-3090, 2008
PubMed
18) Yoshikawa T, Yoshida N, Manabe H, et al : Alpha-tocopherol protects against expression of adhesion molecules on neutrophils and endothelial cells. Biofactors 7 : 15-19, 1998
PubMed
19) Murohara T, Ikeda H, Otsuka Y, et al : Inhibition of platelet adherence to mononuclear cells by alpha-tocopherol : role of P-selectin. Circulation 110 : 141-148, 2004
PubMed
20) Cachia O, Benna J, Pedruzzi E, et al : Alpha-tocopherol inhibits the respiratory burst in human monocytes. Attenuation of p47 (phox) membrane translocation and phosphorylation. J Biol Chem 273 : 32801-32805, 1998
PubMed
21) Devaraj S, Jialal I : Alpha-tocopherol decreases interleukin-1 beta release from activated human monocytes by inhibition of 5-lipoxygenase. Arterioscler Thromb Vasc Biol 19 : 1125-1133, 1999
 
22) Saldeen T, Li D, Mehta J : Differential effects of alpha- and gamma-tocopherol on low-density lipoprotein oxidation, superoxide activity, platelet aggregation and arterial thrombogenesis. J Am Coll Cardiol 34 : 1208-1215, 1999
PubMed
23) Freedman JE, Loscalzo J : Platelet-monocyte aggregates : bridging thrombosis and inflammation. Circulation 105 : 2130-2132, 2002
PubMed
24) Freedman J, Farhat J, Loscalzo J, et al : Alpha-tocopherol inhibits aggregation of human platelets by a protein kinase C-dependent mechanism. Circulation 94 : 2434-2440, 1996
PubMed
25) Rao BN, Anderson MB, Musser JH, et al : Sialyl Lewis X mimics derived from a pharmacophore search are selectin inhibitors with anti-inflammatory activity. J Biol Chem 269 : 19663-19666, 1994
PubMed
26) Kilgore KS, Tanhehco EJ, Park JL, et al : Reduction of myocardial infarct size in vivo by carbohydrate-based glycomimetics. J Pharmacol Exp Ther 284 : 427-435, 1998
PubMed
27) Kim MK, Brandley BK, Anderson MB, et al : Antagonism of selectin-dependent adhesion of human eosinophils and neutrophils by glycomimetics and oligosaccharide compounds. Am J Respir Cell Mol Biol 19 : 836-841, 1998
 
28) Takeshita K, Susuki C, Itoh S, et al : Preventive effect of alpha-tocopherol and glycyrrhizin against platelet-neutrophil complex formation induced by hemodialysis membranes. Int J Artif Organs 32 : 282-290, 2009
PubMed

7 Heterotypic Cell Interactions in Hemodialysis Patients ( 血液透析患者における血液細胞間の相互作用 )

P.76 掲載の参考文献
1) Hakim RM : Clinical implications of hemodialysis membrane biocompatibility. Kidney Int 44 : 484-494, 1993
PubMed
2) Opatrny K Jr : Clinical importance of biocompatibility and its effects on hemodialysis treatment. Nephrol Dial Transplant 18 (Suppl. 5) : 41-44, 2003
 
3) Hakim RM, Schafer AI : Hemodialysis-associated platelet activation and thrombocytopenia. Am J Med 78 : 575-580, 1985
PubMed
4) Gawaz MP, Ward RA : Effects of hemodialysis on platelet-derived thrombospondin. Kidney Int 40 : 257-265, 1991
PubMed
5) Cases A, Reverter JC, Escolar G, et al : Platelet activation on hemodialysis : influence of dialysis membranes. Kidney Int 43 (Suppl 41) : 217-220, 1993
 
6) Kawabata K, Nagake Y, Shikata K, et al : Soluble p-selectin is released from activated platelets in vivo during hemodialysis. Nephron 78 : 148-155, 1998
PubMed
7) Himmelfarb J, Holbrook D, McMonagle E, et al : Increased reticulated platelets in dialysis patients. Kidney Int 51 : 834-839, 1997
PubMed
8) Dhodt A, Vanholder R, Lameire N : Hemodialysis-related bioincompatibility and adhesion molecules. Int J Artif Organs 21 : 501-505, 1998
PubMed
9) Blumenstein M, Ziegler-Heitbrock HWL, Schiller B, et al : Differential activation of monocytes in haemodialysis patients exposed to different types of membranes. Scand J Immunol 31 : 183-188, 1990
 
10) Himmelfarb J, Ault KA, Holbrook D, et al : Intradialytic granulocyte reactive oxygen species production : A prospective, crossover trial. J Am Soc Nephrol 4 : 178-186, 1993
PubMed
11) Bonomini M, Stuard S, Albertazzi A : Cell-associated adhesion molecules in hemodialysis. Int J Immunopathol Pharmacol 10 : 37-44, 1997
 
12) Pereira BJG, Dinarello CA : Production of cytokines and cytokine inhibitory proteins in patients on dialysis. Nephrol Dial Transplant 9 (Suppl. 2) : 60-71, 1994
 
13) Sirolli V, Amoroso L, Pietropaolo M, et al : Platelet-leukocyte interactions in hemodialysis patients : culprit or bystander? Int J Immunopath Pharmacol 19 : 461-470, 2006
PubMed
14) Rinder HM, Bonan JL, Rinder CS, et al : Activated and unactivated platelet adhesion to monocytes and neutrophils. Blood 78 : 1760-1769, 1991
PubMed
15) Rinder HM, Bonan JL, Rinder CS, et al : Dynamics of leukocyte platelet adhesion in whole blood. Blood 78 : 1730-1737, 1991
PubMed
16) Bazzoni G, Dejana E, Del Maschio A : Platelet neutrophil interactions. Possible relevance in the pathogenesis of thrombosis and inflammation. Haematologica 76 : 491-499, 1991
PubMed
17) Wun T, Paglieroni T, Tablin F, et al : Platelet activation and platelet-erythrocyte aggregates in patients with sickle cell anemia. J Lab Clin Med 129 : 507-515, 1997
PubMed
18) Wun T, Paglieroni T, Field CL, et al : Platelet-erythrocyte adhesion in sickle cell disease. J Invest Med 47 (3) : 121-127, 1999
 
19) Faint RW : Platelet-neutrophil interactions : their significance. Blood Rev 6 : 83-91, 1992
PubMed
20) Freedman JE, Loscalzo J : Platelet-monocyte aggregates : bridging thrombosis and inflammation. Circulation 105 : 2130-2132, 2002
PubMed
21) Zarbock A, Polanowska-Grabowska RK, Ley K : Platelet-neutrophil interactions : linking hemostasis and inflammation. Blood Rev 21 : 99-110, 2007
PubMed
22) Santos MT, Valles J, Marcus AJ, et al : Enhancement of platelet reactivity and modulation of eicosanoid production by intact erythrocytes. A new approach to platelet activation and recruitment. J Clin Invest 87 : 571-580, 1991
PubMed
23) Valles J, Santos MT, Aznar J, et al : Erythrocytes metabolically enhance collagen-induced platelet responsiveness via increased thromboxane production, adenosine diphosphate release, and recruitment. Blood 78 : 154-162, 1991
PubMed
24) Craddock PR, Ferh J, Brigham KL, et al : Complement and leukocyte-mediated pulmonary dysfunction in hemodialysis. N Engl J Med 296 : 769-774, 1977
 
25) Larsen E, Celi A, Gilbert GE, et al : PADGEM protein : A receptor that mediates the interaction of activated platelets with neutrophils and monocytes. Cell 59 : 305-312, 1989
PubMed
26) Rinder CS, Bonan JL, Rinder HM, et al : Cardiopulmonary bypass induces leukocyte-platelet adhesion. Blood 79 : 1201-1205, 1992
PubMed
27) Mickelson JK, Lakkis NM, Villarreal-Levy G, et al : Leukocyte activation with platelet adhesion after coronary angioplasty : a mechanism for recurrent disease? J Am Coll Cardiol 28 : 345-353, 1996
 
28) Neumann FJ, Ott I, Gawaz M, et al : Neutrophil and platelet activation at balloon-injured coronary artery plaque in patients undergoing angioplasty. J Am Coll Cardiol 27 : 819-824, 1996
PubMed
29) Ott I, Neumann FJ, Gawaz M, et al : Increased neutrophil-platelet adhesion in patients with unstable angina. Circulation 94 : 1239-1246, 1996
PubMed
30) Faraday N, Braunstein JB, Heldman AW, et al : Prospective evaluation of the relationship between platelet-leukocyte conjugate formation and recurrent myocardial ischemia in patients with acute coronary syndromes. Platelets 15 : 9-14, 2004
PubMed
31) Russwurm S, Vickers J, Meier-Hellmann A, et al : Platelet and leukocyte activation correlate with the severity of septic organ dysfunction. Shock 17 : 263-268, 2002
PubMed
32) Kirschenbaum LA, Adler D, Astiz ME, et al : Mechanisms of platelet-neutrophil interactions and effects on cell filtration in septic shock. Shock 17 : 508-512, 2002
PubMed
33) Peters MJ, Heyderman RS, Faust S, et al : Severe meningococcal disease is characterized by early neutrophil but not platelet activation and increased formation and consumption of plateletneutrophil complexes. J Leukoc Biol 73 : 722-730, 2003
 
34) Pamuk GE, Vural O, Turgut B, et al : Increased circulating platelet-neutrophil, platelet-monocyte complexes, and platelet activation in patients with ulcerative colitis : a comparative study. Am J Hematol 81 : 753-759, 2006
PubMed
35) Tuttle HA, Davis-Gorman G, Goldman S, et al : Platelet-neutrophil conjugate formation is increased in diabetic women with cardiovascular disease. Cardiovasc Diabetol 4 : 2-12, 2003
PubMed
36) Peters MJ, Dixon G, Kotowicz KT, et al : Circulating platelet-neutrophil complexes represent a subpopulation of activated neutrophils primed for adhesion, phagocytosis and intracellular killing. Br J of Haemat 106 : 391-399, 1999
 
37) Evangelista V, Manarini S, Sideri R, et al : Platelet/polymorphonuclear leukocyte interaction : Pselectin triggers protein-tyrosine phosphorylation-dependent CD11b/CD18 adhesion : role of PSGL-1 as a signaling molecule. Blood 93 : 876-885, 1999
PubMed
38) Nash GB : Adhesion between neutrophils and platelets : a modulator of thrombotic and inflammatory events? Thromb Res 74 (Suppl. 1) : S3-S11, 1994
 
39) Evangelista V, Piccardoni P, White JG, et al : Cathepsin-G dependent platelet stimulation by activated polymorphonuclear leukocytes and its inhibition by antiproteinases : Role of P-selectinmediated cell-cell adhesion. Blood 81 : 2947-2957, 1993
 
40) Ware JA, Heistad DD : Platelet endothelium interactions. N Engl J Med 328 : 628-635, 1993
PubMed
41) Gawaz MP, Mujais SK, Schmidt B, et al : Platelet-leukocyte aggregation during hemodialysis. Kidney Int 46 : 489-495, 1994
PubMed
42) Bonomini M, Stuard S, Albertazzi A : Cell-associated adhesion molecules in hemodialysis. Int J Immunopathol Pharmacol 10 : 37-44, 1997
 
43) Stuard S, Bonomini M, Settefrati N, et al : Platelet-neutrophil interactions during hemodialysis : a proposed biocompatibility approach. Int J Artif Organs 21 : 75-82, 1998
PubMed
44) Bonomini M, Sirolli V, Settefrati N, et al : Surface antigen expression and platelet neutrophil interactions in haemodialysis. Blood Purif 17 : 107-117, 1999
PubMed
45) Sirolli V, Ballone E, Di Stante S, et al : Cell activation and cellular-cellular interactions during hemodialysis : effect of dialyzer membrane. Int J Artif Organs 25 : 529-537, 2002
PubMed
46) Sirolli V, Di Stante S, Stuard S, et al : Biocompatibility and functional performance of a polyethylene glicol acid-grafted cellulosic membrane for hemodialysis. Int J Artif Organs 23 : 356-364, 2000
 
47) Sirolli V, Ballone E, Amoroso L, et al : Leukocyte adhesion molecules and leukocyte-platelet interactions during hemodialysis : effects of different synthetic membranes. Int J Artif Organs 22 : 536-542, 1999
PubMed
48) Bonomini M, Di Stante S, Sirolli V : Biocompatibility of DIAPES. Contrib Nephrol 138 : 117-125, 2003
PubMed
49) Itoh S, Susuki C, Tsuji T : Platelet activation through interaction with hemodialysis membranes induces neutrophils to produce reactive oxygen species. J Biomed Mater Res A 77 : 294-303, 2006
PubMed
50) Bonomini M, Stuard S, Carreno MP, et al : Neutrophil reactive oxygen species production during hemodialysis : role of activated platelet adhesion to neutrophils through P-selectin. Nephron 75 : 402-411, 1997
PubMed
51) Yang J, Furie BC, Furie B : The biology of P-selectin glycoprotein ligand-1；its role as a counter receptor in leukocyte-endothelial and leukocyte-platelet interaction. Thromb Haemost 81 : 1-7, 1999
PubMed
52) Ruf A, Patscheke H : Platelet-induced neutrophil activation : platelet-expressed fibrinogen induces the oxidative burst in neutrophils by an interaction with CD11C/CD18. Br J Haematol 90 : 791-796, 1995
PubMed
53) Carreno MP, Stuard S, Bonomini M, et al : Cell-associated adhesion molecules as early markers of bioincompatibility. Nephrol Dial Transplant 11 : 2248-2257, 1996
PubMed
54) Stuard S, Carreno MP, Poignet JL, et al : A major role for CD62P/CD15s interaction in leukocyte margination during hemodialysis. Kidney Int 48 : 93-102, 1995
 
55) Itoh S, Takeshita K, Susuki C, et al : Redistribution of P-selectin ligands on neutrophil cell membranes and the formation of platelet-neutrophil complex induced by hemodialysis membranes. Biomaterials 29 : 3084-3090, 2008
PubMed
56) Nagata K, Tsuji T, Todoroki N, et al : Activated platelets induce superoxide anion release by monocytes and neutrophils through P-selectin. J Immunol 151 : 3267-3273, 1993
PubMed
57) Koike J, Nagata K, Kudo S, et al : Density-dependent induction of TNF-α release from human monocytes by immobilized P-selectin. FEBS Lett 477 : 84-88, 2000
 
58) Schomig M, Eisenhardt A, Ritz E : The microinflammatory state of uremia. Blood Purif 8 : 327-332, 2000
 
59) Rosenkranz AR, Templ E, Traindl O, et al : Reactive oxygen product formation by human neutrophils as an early marker for biocompatibility of dialysis membrane. Clin Exp Immunol 98 : 300-305, 1994
PubMed
60) Cappelliere-Blandin C, Delaveau T, Descamps-Latscha B : Structural modifications of human beta 2-microglobulin treated with oxygen-derived radicals. Biochem J 277 : 175-182, 1991
 
61) Malech HL, Gallin JI : Neutrophils in human diseases. N Engl J Med 317 : 887-894, 1987
 
62) Holliwell B : The role of oxygen radicals in human disease, with particular reference to the vascular system. Haemostasis 23 (Suppl. 1) : 118-128, 1993
 
63) Yagi K : A biochemical approach to atherogenesis. Trends Biochem Sci 11 : 18-19, 1986
 
64) Linder A, Charna B, Sherrand DJ, et al : Accelerated atherosclerosis in prolonged maintenance hemodialysis. N Engl J Med 290 : 697-701, 1974
 
65) Amann K, Gross ML, Ritz E : Pathophysiology underlying accelerated atherogenesis in renal disease : closing in on the target. J Am Soc Nephrol 15 : 1664-1666, 2004
 
66) Galle J, Wanner C : Oxidative stress and vascular injury-relevant for atherogenesis in uraemic patients? Nephrol Dial Transplant 12 : 2480-2483, 1997
PubMed
67) Takeshita K, Susuki C, Itoh S, et al : Preventive effect of T-tocopherol and glycyrrhizin against platelet-neutrophil complex formation induced by hemodialysis membranes. Int J Artif Organs 32 : 282-290, 2009
 
68) Murohara T, Ikeda H, Otsuka Y, et al : Inhibition of platelet adherence to mononuclear cells by α-tocopherol : role of P-selectin. Circulation 110 : 141-148, 2004
 
69) Nakata N, Takaoka K : Use of glycyrrhizin in prevention of tissue damage caused by ischemiareperfusion in rabbit hind limbs. J Orthop Sci 11 : 375-379, 2006
PubMed
70) Kim MK, Brandley BK, Anderson MB, et al : Antagonism of selectin-dependent adhesion of human eosinophils and neutrophils by glycomimetics and oligosaccharide compounds. Am J Respir Cell Mol Biol 19 : 836-841, 1998
 
71) Neumann FJ, Zohlnhofer D, Fakhoury L, et al : Effect of glycoprotein IIb/IIIa receptor blockade on platelet-leukocyte interaction and surface expression of the leukocyte integrin Mac-1 in acute myocardial infarction. J Am Coll Cardiol 34 : 1420-1426, 1999
PubMed
72) Celi A, Pellegrini G, Lorenzet R, et al : P-selectin induces the expression of tissue factor on monocytes. Proc Natl Acad Sci USA 91 : 8767-8771, 1994
PubMed
73) Neumann FJ, Marx N, Gawaz M, et al : Induction of cytokine expression in leukocytes by binding of thrombin-stimulated platelets. Circulation 95 : 2387-2394, 1997
PubMed
74) Weyrich AS, McIntyre TM, McEver RP, et al : Monocyte tethering by P-selectin regulates monocyte chemotactic protein-1 and tumor necrosis factor-α secretion. Signal integration and NF-kappaB translocation. J Clin Invest 95 : 2297-2303, 1995
 
75) Huo Y, Ley FK : Role of platelets in the development of atherosclerosis. Trends Cardiovasc Med 14 : 18-22, 2004
 
76) Li N, Hu H, Lindquist M, et al : Platelet-leukocyte cross talk in whole blood. Arterioscler Thromb Vasc Biol 20 : 2702-2708, 2000
 
77) Huo Y, Schober A, Forlow SB, et al : Circulating activated platelets exacerbate atherosclerosis in mice deficient in apolipoprotein E. Nat Med 9 : 61-67, 2003
PubMed
78) Van der Wal AC, Becker AE : Atherosclerotic plaque rupture-basis of plaque stability and instability. Cardiovasc Res 41 : 334-344, 1999
PubMed
79) Michelson AD, Barnard MR, Krueger LA, et al : Circulating monocyte-platelet aggregates are a more sensitive marker of in vivo platelet activation than platelet surface P-selectin : studies in baboons, human coronary intervention, and human acute myocardial infarction. Circulation 104 : 1533-1537, 2001
 
80) Furman MI, Benoit SE, Barnard MR, et al : Increased platelet reactivity and circulating monocyteplatelet aggregates in patients with stable coronary artery disease. J Am Coll Cardiology 31 : 352-358, 1998
 
81) Furman MI, Barnard MR, Krueger LA, et al : Circulating monocyte-platelet aggregates are an early marker of acute myocardial infarction. J Am Coll Cardiology 38 : 1002-1006, 2001
 
82) Sarma J, Laan CA, Alam S, et al : Increased platelet binding to circulating monocytes in acute coronary syndromes. Circulation 105 : 2166-2171, 2002
PubMed
83) Wang J, Zhang S, Jin Y, et al : Elevated levels of platelet-monocyte aggregates and related circulating biomarkers in patients with acute coronary syndrome. Int J Cardiol 115 : 361-365, 2007
 
84) Harding SA, Sommerfield AJ, Sarma J, et al : Increased CD40 ligand and platelet-monocyte aggregates in patients with type 1 diabetes mellitus. Atherosclerosis 176 : 321-325, 2004
PubMed
85) Elelamy I, Chakrown T, Gerotziafas GT, et al : Circulating platelet-leukocyte aggregates : a marker of microvascular injury in diabetic patients. Thromb Res 121 : 843-848, 2008
 
86) Villmow T, Kemkes-Matthes B, Matzdorff AC : Markers of platelet activation and platelet-leukocyte interaction in patients with myeloproliferative syndromes. Thromb Res 108 : 139-145, 2002
PubMed
87) Wun T, Cordoba M, Rangaswami A, et al : Activated monocytes and platelet-monocyte aggregates in patients with sickle cell disease. Clin Lab Haematol 24 : 81-88, 2002
PubMed
88) Tsai NW, Chang WN, Shaw CF, et al : Levels and value of platelet activation markers in different subtypes of acute non-cardio-embolic ischemic stroke. Thromb Res 124 : 213-218, 2009
PubMed
89) Ray MJ, Walters DL, Bett JN, et al : Platelet-monocyte aggregates predict troponin rise after percutaneous coronary intervention and are inhibited by abciximab. Int J Cardiol 101 : 249-255, 2005
PubMed
90) Ashman N, Macey MG, Fan SL, et al : Increased platelet-monocyte aggregates and cardiovascular disease in end-stage renal failure patients. Nephrol Dial Transplant 18 : 2088-2096, 2003
PubMed
91) Kawabata K, Nakai S, Miwa M, et al : Platelet GPIIb/IIIa is activated and platelet-leukocyte coaggregates formed in vivo during hemodialysis. Nephron 90 : 391-400, 2002
PubMed
92) Henn V, Slupsky JR, Grafe M, et al : CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 391 : 591-594, 1998
PubMed
93) Schonbeck U, Libby P : CD40 signaling and plaque instability. Circ Res 89 : 1092-1103, 2001
PubMed
94) May AE, Langer H, Seizer P, et al : Platelet-leukocyte interactions in inflammation and atherothrombosis. Semin Thromb Hemost 33 : 123-127, 2007
PubMed
95) van Gils JM, Zwaginga JJ, Hordiik PC : Molecular and functional interactions among monocytes, platelets, and endothelial cells and their relevance for cardiovascular diseases. J Leuk Biol 85 : 195-204, 2009
 
96) Valles J, Santos MT, Aznar J, et al : Erythrocyte promotion of platelet reactivity decreases the effectiveness of aspirin as an antithrombotic therapeutic modality : the effect of low-dose aspirin is less than optimal in patients with vascular disease due to prothrombotic effects of erythrocytes on platelet reactivity. Circulation 97 : 350-355, 1998
PubMed
97) Santos MT, Valles J, Aznar J, et al : Aspirin therapy for inhibition of platelet reactivity in the presence of erythrocytes in patients with vascular disease. J Lab Clin Med 147 : 220-227, 2006
PubMed
98) Santos MT, Valles J, Lago A, et al : Residual platelet thromboxane A2 and prothrombotic effects of erythrocytes are important determinants of aspirin resistance in patients with vascular disease. J Thromb Haemost 6 : 615-621, 2008
PubMed
99) Francis RB, Johnson CS : Vascular occlusion in sickle cell disease : current concepts and unanswered questions. Blood 77 : 1405-1414, 1991
PubMed
100) Sirolli V, Strizzi L, Di Stante S : Platelet activation and platelet-erythrocyte aggregates in endstage renal disease patients on hemodialysis. Thromb Haemost 86 : 834-839, 2001
PubMed
101) Mohri H : Fibronectin and integrins interactions. J Invest Med 44 : 429-441, 1996
 
102) Bonomini M, Pavone B, Sirolli V, et al : Proteomics characterization of protein adsorption onto hemodialysis membranes. J Prot Res 5 : 2666-2674, 2006
 

8 Biocompatibility profile of Ethylen - vinyl - alcohol ( EVAL ), a synthetic dialytic membrane with reduced coagulation and inflammatory activity ( 凝固系活性化および催炎症作用が少ない合成透析膜「エチレンビニルアルコール ( EVAL膜 ) 」の生体適合性の特徴 )

P.104 掲載の参考文献
1) Kaysen GA : The microinflammatory state in uremia. Causes and potential consequences. J Am Soc Nephrol 12 : 1549-1557, 2001
 
2) Osterud B, Bjorklid E : Role of monocytes in atherogenesis. Physiol Rev 83 : 1069-1112, 2003
PubMed
3) Hansson GK : Inflammation, atherosclerosis and coronary artery disease. N Engl J Med 352 : 1685-1695, 2005
PubMed
4) Davies MR, Hruska KA : Pathophysiological mechanisms of vascular calcification in end-stage renal disease. Kidney Int 60 : 472-479, 2001
PubMed
5) Yeun JY, Levine RA, Mantadilok V, et al : C-Reactive protein predicts all-cause and cardiovascular mortality in hemodialysis patients. Am J Kidney Dis 35 : 469-476, 2000
PubMed
6) Zimmermann J, Herrlinger S, Pruy A, et al : Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int 55 : 648-658, 1999
PubMed
7) Akahoshi T, Kobayashi N, Hosaka S, et al : In vivo induction of monocyte chemotactic and activating factor in patients with chronic renal failure. Nephrol Dial Transplant 10 : 2244-2249, 1995
PubMed
8) Memoli B, Grandaliano G, Soccio M, et al : In vivo modulation of soluble "antagonistic" IL-6 receptor synthesis and release in end stage renal disease. J Am Soc Nephrol 16 : 1099-1107, 2005
PubMed
9) Lonnemann G, VanDer Meer JW, Cannon JG, et al : Induction of tumor necrosis factor during extracorporeal blood purification. N Engl J Med 317 : 963-964, 1987
 
10) Nakanishi I, Moutabarrik A, Okada N, et al : Interleukin-8 in chronic renal failure and dialysis patients. Nephrol Dial Transplant 9 : 1435-1442, 1994
PubMed
11) Gesualdo L, Pertosa G, Grandaliano G, et al : Cytokines and bioincompatibility. Nephrol Dial Transplant 13 : 1622-1626, 1998
PubMed
12) Pertosa G, Grandaliano G, Gesualdo L, et al : Interleukin-6, interleukin-8 and monocyte chemotactic peptide-1 gene expression and protein synthesis are independently modulated by hemodialysis membranes. Kidney Int 54 : 570-579, 1998
PubMed
13) Leonard EJ, Yoshimura T : Human monocyte chemoattractant protein-1 (MCP-1). Immunol Today 11 : 97-101, 1990
PubMed
14) Charo IF, Myers SJ, Herman A, et al : Molecular cloning and functional expression of two monocyte chemoattractant protein 1 receptors reveals alternative splicing of the carboxyl-terminal tails. Proc Natl Acad Sci USA 91 : 2752-2756, 1994
PubMed
15) Rayner K, Van Eersel S, Groot PH, et al : Localisation of mRNA for JE/MCP-1 and its receptor CCR2 in atherosclerotic lesions of the ApoE knockout mouse. J Vasc Res 37 : 93?102, 2000
 
16) Pertosa G, Grandaliano G, Soccio M, et al : Vitamin E-modified filters modulate jun n-terminal kinase activation in peripheral blood mononuclear cells. Kidney Int 62 : 602-610, 2002
PubMed
17) Gesualdo L, Pertosa G, Grandaliano G, et al : Cytokines and bioincompatibility. Nephrol Dial Transplant 13 : 1622-1626, 1998
PubMed
18) Walter R, Mischak H, Haller H : Haemodialysis, atherosclerosis and inflammation-identifying molecular mechanisms of chronic vascular disease in ESRD patients. Nephrol Dial Transplant 17 (Suppl 3) : 24-29, 2002
 
19) Sagedal S, Hartmann A, Sundstrom K, et al : Anticoagulation intensity sufficient for hemodialysis does not prevent activation of coagulation and platelets. Nephrol Dial Transplant 16 : 987-993, 2001
 
20) Altieri DC, Edgington TS : Identification of effector cell protease receptor-1 : a leukocytedistributed receptor for the serine protease factor Xa. J Immunol 145 : 246-253,1990
PubMed
21) Coughlin SR : Protease-activated receptors start a family. Proc Natl Acad Sci USA 91 : 9200-9202, 1994
 
22) Bono F, Schaeffer P, Herault JP, et al : Factor Xa activates endothelial cells by a receptor cascade between EPR-1 and PAR-2. Arterioscler Thromb Vasc Biol 20 : 107-112, 2000
 
23) Gasic GP, Arenas CP, Gasic TB, et al : Coagulation factors X, Xa, and protein S as potent mitogens of cultured aortic smooth muscle cells. Proc Natl Acad Sci USA 89 : 2317-2320, 1992
PubMed
24) Ko FN, Yang YC, Huang SC, et al : Coagulation factor Xa stimulates platelet-derived growth factor release and mitogenesis in cultured vascular smooth muscle cells of rat. J Clin Invest 98 : 1493-1501, 1996.
 
25) Papapetropoulos A, Piccardoni P, Cirino G, et al : Hypotension and inflammatory cytokine gene expression triggered by factor Xa-nitric oxide signaling. Proc Natl Acad Sci USA 95 : 4738-4742, 1998
PubMed
26) Lo YYC, Wong JMS, Cruz TF : Reactive oxygen species mediate cytokine activation of c-Jun NH2-terminal kinases. J Biol Chem 271 : 15703-15707, 1996
 
27) Ishii Y, Yano S, Kanai H, et al : Evaluation of blood coagulation-fibrinolysis system in patients receiving chronic hemodialysis. Nephron 73 : 407-412, 1996
PubMed
28) Pertosa G, Simone S, Soccio M, et al : Coagulation Cascade Activation Causes CC Chemokine Receptor-2 Gene Expression and Mononuclear Cell Activation in Hemodialysis Patients. J Am Soc Nephrol 16 : 2477-2486, 2005
PubMed
29) Boring L, Gosling J, Cleary M, et al : Decreased lesion formation in CCR2-/-mice reveals a role for chemokines in the initiation of atherosclerosis. Nature 394 : 894?897, 1998.
 
30) Gosling J, Slaymaker S, Gu L, et al : MCP-1 deficiency reduces susceptibility to atherosclerosis in mice that overexpress human apolipoprotein B. J Clin Invest 103 : 773-780, 1999
PubMed
31) Morena M, Delbosc S, Dupuy AM, et al : Overproduction of reactive oxygen species in end-stage renal disease patients : a potential component of hemodialysis-associated inflammation. Hemodial Int 9 (1) : 37-46, 2005
PubMed
32) Morena M, Cristol JP, Senecal L, et al : Oxidative stress in hemodialysis patients : is NADPH oxidase complex the culprit? Kidney Int 80 : 109-114, 2002
PubMed
33) Simone S, Cariello M, Pietanza S, et al : NADPH oxidase complex activation and overproduction of reactive oxygen species (ROS) in hemodialysis (HD) patients treated with synthetic membranes. Am Soc Nephrol Meeting PO2553, 2009.
 
34) Foley RN, Parfrey PS, Sarnak MJ : Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 32 : S112-S119, 1998.
PubMed
35) Muntner P, He J, Hamm L, et al : Renal insufficiency and subsequent death resulting from cardiovascular disease in the United States. J Am Soc Nephrol 13 : 745-753, 2002
PubMed
36) Davies MR, Hruska KA : Pathophysiological mechanisms of vascular calcification in end-stage renal disease. Kidney Int 60 : 472-479, 2001
PubMed
37) Raggi P, Boulay A, Chasan-Taber S, et al : Cardiac calcification in adult hemodialysis patients. A link between end-stage renal disease and cardiovascular disease? J Am Coll Cardiol 39 : 695-701, 2002
PubMed
38) Jakoby MG 4th, Semenkovich CF : The role of osteoprogenitors in vascular calcification. Curr Opin Nephrol Hypertens 9 : 11-15, 2000
PubMed
39) Moe SM, Chen NX : Mechanisms of Vascular Calcification in Chronic Kidney Disease. J Am Soc Nephrol 19 : 213-216, 2008
 
40) Ketteler M, Bongartz P, Westenfeld R, et al : Association of low fetuin-A concentrations in serum with cardiovascular mortality in patients on dialysis : A cross-sectional study. Lancet 361 : 827-833, 2003
PubMed
41) Pertosa G, Simone S, Ciccone M, et al : Serum Fetuin-A in hemodialysis : a link between derangement of calcium-phosphorus homeostasis and progression of atherosclerosis? Am J Kidney Dis 53 : 467-474, 2009
PubMed
42) Pertosa G, Simone S, Porreca S, et al : Association of chronic microinflammation, progression of atherosclerosis and outcome in maintenance hemodialysis (HD) : long term effect of dialytic membranes. Nephrol Dial Transplant 21 (S4) : iv444, 2006
 
43) Bostrom K, Watson KE, Horn S, et al : Bone morphogenetic protein expression in human atherosclerotic lesions. J Clin Invest 91 : 1800-1809, 1993
PubMed
44) Dhore CR, Cleutjens JP, Lutgens E, et al : Differential expression of bone matrix regulatory proteins in human atherosclerotic plaques. Arterioscler Thromb Vasc Biol 21 : 1998-2003, 2001
PubMed
45) Davies MR, Lund RJ, Mathew S, et al : Low turnover osteodystrophy and vascular calcification are amenable to skeletal anabolism in an animal model of chronic kidney disease and the metabolic syndrome. J Am Soc Nephrol 16 : 917-928, 2005
 
46) Pertosa G, Dalfino G, Porreca S, et al : Inflammation-related imbalance in bone morphogenetic proteins (BMPs) production may favour the progression of cardiovascular disease in dialysis patients. Nephrol Dial Transplant 22 : 315A, 2007
 
47) Pertosa G, Dalfino G, Porreca S, et al : Low coagulation-activating dialyzer reduces progression of atherosclerosis in hemodialysis (HD) modulating serum bone morphogenetic proteins (BMPs) . J Am Soc Nephrol 18 : 274A, 2007
 

9 蛋白リーク膜の溶質除去と臨床効果

P.112 掲載の参考文献
1) Babb AL, Popovich RP, Christopher TG, et al : The genesis of the square meter-hour hypothesis. Trans Am Soc Artif Intern Organs 17 : 81-90, 1971
PubMed
2) 斎藤明, 高木豊巳, 鄭大基, 他 : Protein-loosing hemofilterの臨床と濾液中の中・高分子物質の分析. 人工臓器 10 : 907, 1981
 
3) Gejyo F, Yamada T, Odani S, et al : A new form of amyloid protein associated with chronic hemodialysis was identified as β2-microglobulin. Biochem Biophys Res Commun 129 : 701-706, 1985
 
4) 小早川裕之, 新里高弘, 高井一郎, 他 : 関節痛を訴える長期透析患者のpush-pull HDFあるいはHDによる治療. 腎と透析 25 別冊ハイパフォーマンスメンブレン '88 : 133-136, 1988
 
5) 小山誠, 熊野和雄, 南部正人, 他 : 各種HPM 透析における大分子量物質除去能と肩関節痛軽減効果の検討. 腎と透析 30 別冊ハイパフォーマンスメンブレン '91 : 100-104, 1991
 
6) 友雅司 : 腎不全患者の血液浄化におけるアルブミンリークの意義. 腎と透析 65 別冊ハイパフォーマンスメンブレン '08 : 13-17, 2008
 
7) 水口潤, 土田健司, 中村雅将 : 低分子量蛋白領域の尿毒症物質除去とアルブミン損失. 腎と透析 65 別冊ハイパフォーマンスメンブレン '08 : 18-22, 2008
 
8) 宍戸寛治, 高山公洋, 中島豊, 他 : タンパク透過性血液濾過透析の臨床効果. 腎と透析 21 別冊ハイパフォーマンスメンブレン '86 : 48-51, 1986
 
9) 小林肇, 小笠原雅幸, 長谷川豊, 他 : Protein Permeable Hemodialysisの臨床効果. 腎と透析 21 別冊ハイパフォーマンスメンブレン '86 : 56-61, 1986
 
10) 上野幸司, 渡辺有義, 青柳秀夫, 他 : HPMの貧血改善効果について (第2報). 腎と透析 28 別冊ハイパフォーマンスメンブレン '90 : 90-93, 1990
 
11) 宮崎哲夫, 内藤秀宗 : 長期 (3年間) PPHDの臨床経験. 腎と透析 21 別冊ハイパフォーマンスメンブレン '86 : 52-55, 1986
 
12) 小川洋史, 高木豊巳, 高井一郎, 他 : 従来のダイアライザーと蛋白透過型ダイアライザーの併用療法の長期臨床評価. 腎と透析 21 別冊ハイパフォーマンスメンブレン '86 : 62-65, 1986
 
13) 佐々木弘州, 佐藤隆, 池松秀樹, 他 : BK-1.6Pを用いたPPHDの臨床評価. 腎と透析 25 別冊ハイパフォーマンスメンブレン '88 : 91-94, 1988
 
14) 宮崎哲夫, 長坂肇, 内藤秀宗 : ハイパフォーマンスメンブレン膜の長期臨床使用経験. 腎と透析 30 別冊ハイパフォーマンスメンブレン '91 : 92-96, 1991
 
15) 水口潤, 川島周, 宮崎哲夫, 他 : 改良型EVAL膜ダイアライザー (EVAL-CH) によるアミロイド骨関節痛の治療効果. 腎と透析 32 別冊ハイパフォーマンスメンブレン '92 : 82-85, 1992
 
16) 新里健, 中村博文, 有吉正一, 他 : 各種高機能膜 (HPM) による臨床症状の改善. 腎と透析 34 別冊ハイパフォーマンスメンブレン '93 : 158-163, 1993
 
17) 水口潤, 内藤秀宗, 斎藤明, 他 : 蛋白透過型フィルター (EVAL-CH) を使用したmini HDFによる補体Factor D除去の試み. 腎と透析 43 別冊ハイパフォーマンスメンブレン '97 : 161-163, 1997
 
18) 水口潤, 内藤秀宗, 斎藤明, 他 : HDF療法によるfactor D除去と生体適合性. 腎と透析 45 別冊ハイパフォーマンスメンブレン '98 : 20-23, 1998
 
19) 水口潤, 鈴江信行 : 大量のアルブミン喪失を伴うHDFが生命予後に与える影響. 腎と透析 51 別冊HDF療法 '01 : 18-20, 2001
 
20) 土田健司, 中村雅将, 吉川和寛, 他 : 各種HPMの長期成績-特にアルブミン漏出量による比較-. 腎と透析 65 別冊ハイパフォーマンスメンブレン '08 : 33-38, 2008
 
21) 川原和彦, 水口潤, 島健二, 他 : 慢性腎不全患者の血清中酸化・還元アルブミン分画の検討. 腎と透析 55 別冊ハイパフォーマンスメンブレン '03 : 179-182, 2003
 

10 微小循環に対する透析膜の影響

P.120 掲載の参考文献
1) 小田稔, 角門真二, 秋澤忠男 : 透析機器に関する生体適合性の基本的な考え方. 臨牀透析 20 : 511-516, 2004
 
2) Miyazaki H, Matsuoka H, Itabe H, et al : Hemodialysis impairs endothelial function via oxidative stress : effects of vitamin E-coated dialyzer. Circulation 101 : 1002-1006, 2000
PubMed
3) Sirolli V, Ballone E, Amoroso L, et al : Leukocyte adhesion molecules and leukocyte-platelet interactions during hemodialysis : effects of different synthetic membranes. Int J Artif Organs 22 : 536-542, 1999
PubMed
4) Sirolli V, Ballone E, Di Stante S, et al : Cell activation and cellular-cellular interactions during hemodialysis : effect of dialyzer membrane. Int J Artif Organs 25 : 529-537, 2002
PubMed
5) Sato M, Morita H, Ema H, et al : Effect of different dialyzer membranes on cutaneous microcirculation during hemodialysis. Clin Nephrol 66 : 426-432, 2006
PubMed
6) 佐藤元美, 天野泉 : 効率面のみに捕らわれない患者本位の膜の選択. Clinical Engineering 18 : 138-142, 2007
 
7) 佐藤元美, 江藤公美, 森田弘之, 他 : 血液透析中の血液粘度の変化に対する透析膜の影響. 腎と透析 57 別冊ハイパフォーマンスメンブレン '04 : 151-153, 2004
 
8) 佐藤元美, 天野泉 : 微小循環, 皮膚組織への酸素供給能の観点からみたダイアライザ生体適合性. 臨牀透析 20 : 569-573, 2004
 
9) 高橋秀一, 櫻田克己, 杉本親紀, 他 : エバブレンEKにおけるバイオインピーダンス法を用いた末梢循環評価. 腎と透析 65 別冊ハイパフォーマンスメンブレン '08 : 271-274, 2008
 
10) 及川一彦, 畠山伸, 佐藤政範, 他 : 透析中の末梢循環変動とウレアのクリアスペース. 腎と透析 56 別冊ハイパフォーマンスメンブレン '04 : 157-160, 2004
 

11 EVAL膜による透析患者の栄養状態の改善

P.129 掲載の参考文献
1) 牟田俊幸, 藤本貴之, 原田康雄, 他 : 膜素材により透析中のアミノ酸漏出に差があるだろうか. 腎と透析 59 別冊ハイパフォーマンスメンブレン '05 : 241-244, 2005
 
2) 牟田俊幸, 原田康雄, 河上由加, 他 : 膜素材による透析中のアミノ酸漏出の差は単にダイアライザの除去性能によるだろうか. 腎と透析 63 別冊ハイパフォーマンスメンブレン '07 : 290-293, 2007
 
3) 牟田俊幸, 河上由加, 山田一代, 他 : EVAL膜による血液透析は透析患者の栄養状態を改善するだろうか-透析患者の栄養状態にダイアライザの膜素材が関与するであろうか (第2報) -. 腎と透析 63 別冊ハイパフォーマンスメンブレン '07 : 294-297, 2007
 
4) 河上由加, 山田一代, 牟田俊幸, 他 : 血液透析中の経静脈栄養補給 (IDPN) にダイアライザの膜素材は影響するであろうか. 腎と透析 65 別冊ハイパフォーマンスメンブレン '08 : 241-297, 2008
 
5) 金成泰, 安本守, 朝部廣美, 他 : クリアスペース率 (M/C (0) /V (te)) によるウレア除去不均一性の評価. 腎と透析 38 別冊ハイパフォーマンスメンブレン '95 : 233-235, 1995
 
6) Yamada K, Furuya R, Takita T, et al : Simplified nutritional screening tools for patients on maintenance hemodialysis. Am J Clin Nutr 87 (1) : 106-113, 2008
PubMed
7) Navarro JF, Marcen R, Teruel JL, et al : Effect of different membranes on amino-acids losses during hemodialysis. Nephrol Dial Trnansplant 13 : 113-117, 1998
PubMed
8) Navarro JF, Mora C, Leon C, et al : Amino acids losses during hemodialysis with polyacrylonitrile membranes : effect of intradialytic amino acid supplementation on plasma amino acid concentrations and nutritional variables in nondiabetic patients. Am J Clin Nutr 71 : 765-773, 2000
PubMed
9) Tepper T, Hem GK, Tuma GJ, et al : Loss of amino acids during hemodialysis : quantitative and qualitative investigations. Clin Nephrol 10 : 16-20, 1978
PubMed
10) Gutierrez A, Bergstrom J, Alvestrand A : Protein catabolism in sham-hemodialysis : the effect of different membranes. Clin Nephrol 38 : 20-29, 1992
PubMed
11) Sirolli V, Ballone E, Amoroso L, et al : Leukocyte adhesion molecules and leukocyte-platelet interactions during hemodialysis : effects of different synthetic membranes. Int J Artif Organs 22 : 536-542, 1999
PubMed
12) Sato M, Morita H, Ema H, et al : Effect of different dialyzer membranes on cutaneous microcirculation during hemodialysis. Clin Nephrol 66 : 426-432, 2006
PubMed
13) 秋葉隆編 : V. 血液透析患者の1年生命予後に関する因子T. body mass index. わが国の慢性透析療法の現況2000年12月31日現在, pp504, 日本透析医学会統計調査委員会, 2001
 
14) 椿原美治, 飯田喜俊, 他 : 慢性透析患者における蛋白・アミノ酸代謝異常と必須アミノ酸療法の検討. 日腎誌XXIV (10) : 1127-1136, 1982
 

12 血圧低下の防止 - EK ( EVAL ) 膜による透析低血圧の予防

P.137 掲載の参考文献
1) 日本透析医学会統計調査委員会 : わが国の慢性透析療法の現況 (2005年12月31日現在), 日本透析医学会, 2006
 
2) 日本透析医学会統計調査委員会 : わが国の慢性透析療法の現況 (2008年12月31日現在), 日本透析医学会, 2009
 
3) 三瀬直文, 杉本徳一郎 : 透析患者さんの高血圧および低血圧はなぜ起きる? 透析ケア 8 : 14-18, 2002
 
4) 関谷秀介, 木村健二郎 : 血圧調整異常. 腎と透析 63 : 705-709, 2007
Medical*Online
5) 竹内恒夫, 菅野義彦, 岡田浩一, 他 : 血圧異常の対応. 腎と透析 60 : 719-724, 2006
 
6) 佐藤元美, 天野泉 : ポリスルフォン膜全盛時代の終焉? 効率面のみに捕らわれない患者本位の膜の選択. Clinical Engineering 18 : 138-142, 2007
 
7) 佐藤元美, 松本芳博, 依馬弘忠, 他 : 透析患者における微小循環に対する透析膜の影響. 腎と透析 53 別冊ハイパフォーマンスメンブレン '02 : 122-124, 2002
 
P.143 掲載の参考文献
1) Stenvinkel P, Heimbuger O, Paultre F, et al : Strong associations between malnutrition, inflammation and atherosclerosis in chronic renal failure. Kidney Int 55 : 1899-1911, 1999
 
2) Henderson LW, Koch KM, Dinarello CA, et al : Hemodialysis hypotention : The interleukin hypothesis. Blood Purif 1 : 3-8, 1983
 
3) 日本透析医学会統計調査委員会 : わが国の慢性透析の現況 (2008年12月31日現在), 日本透析医学会, 2009
 
4) Craddock PR, Fehr J, Dalmasso AP, et al : Hemodialysis leucopenia : pulmonary vascular leukostasis resulting from complement activation by dialyzer cellophane membranes. J Clin Invest 59 : 879-888,1977
PubMed
5) Chenoweth DE : Complement activation during hemodialysis : clinical observations, proposed mechanisms and theoretical implications. Artif Organs 8 : 281-287, 1984
PubMed
6) 中山文義 : 血液浄化療法用素材の生体適合性, 走査電顕による血液付着の解析. 人工臓器 15 : 1857-1867, 1986
 
7) Knudsen F, Nielsen AH, Pedersen JO, et al : Adult respiratory distress-like syndrome during hemodialysis : relationship between activation of complement, leucopenia, and release of granulocyte elastase. Int J Artif Organs 8 : 187-194, 1985
PubMed
8) Nguyen AT, Lethias C, Zingraff J, et al : Hemodialysis membrane-induced activation of phagocyte oxidative metabolism detected in vitro and in vivo within microamounts of whole blood. Kidney Int 28 : 158-167,1985
PubMed
9) Miyata T, Ueda Y, Yamada Y, et al : Accumulation of carbonyls accelerates the formation of pentosidine, an advanced glycation end product : Carbonyl stress in uremia. J Am Soc Nephrol 9 : 2349-2356, 1998
PubMed
10) Miyata T, Inagi R, Iida Y, et al : Involvement ofβ2-microglobulin modified with advanced glycation end products in the pathogenesis of hemodialysis-associated amyloidosis : Induction of human monocyte chemotaxis and macrophage secretion of tumor necrosis factor-α and interleukin 1. J Clin Invest 93 : 521-528,1994
 

13 高齢者社会の維持透析 - 現況とあり方 -

P.151 掲載の参考文献
1) 日本透析医学会統計調査委員会 : 図説わが国の慢性透析療法の現況 (2008年12月31日現在), 日本透析医学会, 2009
 
2) 日本透析医学会統計調査委員会 : 図説わが国の慢性透析療法の現況 (2005年12月31日現在), 日本透析医学会, 2006
 
3) 日本透析医学会統計調査委員会 : 図説わが国の慢性透析療法の現況 (2006年12月31日現在), 日本透析医学会, 2007
 
4) 日本透析医学会統計調査委員会 : 図説わが国の慢性透析療法の現況 (2002年12月31日現在), 日本透析医学会, 2003
 
5) 太田圭洋, 隈博政, 大平整爾, 他 : 通院困難な透析患者への対応及び長期入院透析患者の実態調査. 日透医誌 22 (3) : 342-357, 2007
 
6) Murtagh FE, Marsh JE, Donohoe P, et al : Dialysis or not? A comparative survival study of patients over 75 years with chronic kidney disease stage 5. Nephrol Dial Transplant 22 (7) : 1955-1962, 2007
PubMed
7) 大平整爾 : 高齢者が透析を受ける意味. 臨牀透析 24 (11) : 1481-1490, 2008
 
8) 大平整爾 : 終末期にある透析患者の治療継続と中止およびその後の加療. 臨牀透析 25 (10) : 1397-1402, 2009
 
9) 大平整爾 : 透析非導入 (見送り) と透析中止 (差し控え) への一考察. 透析会誌 41 (11) : 761-770, 2008
 
10) Dasgupta I, Rayner HC : In good conscience-safely withholding dialysis in the elderly. Semin Dial 22 (5) : 476-479, 2009
PubMed
11) Couchoud C, Labeeuw M, Moronne O, et al : A clinical score to predict 6-month prognosis in elderly patients starting dialysis for end-stage renal disease. Nephrol Dial Transplant 24 (5) : 1553-1561, 2009
 
12) 川口良人 : わが国のPD療法確立のために. 腎と透析 66 別冊腹膜透析 2009 : 9-13, 2009
 
13) 峰島三千男 : 血液浄化器, 治療条件の選択. 血液透析 : 安全ガイドブック, 大平整爾, 伊丹儀友編, pp 98-116, 診断と治療社, 東京, 2008
 
14) 村田久行 : スピリチュアルケアをこう考える～スピリチュアルケアにおける教育と研修. 緩和ケア 19 : 25-27, 2009
 

書評

最近チェックした商品履歴

Loading...